FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Lupin Pharmaceuticals Kaitlib Fe norethindrone and ethinyl Recall

Kaitlib Fe norethindrone and ethinyl estradiol chewable tablets (0

Lupin Pharmaceuticals Inc. · Baltimore, MD

Risk level
Class II
Reported by FDA
Aug 7, 2019
Recall ID
D-1565-2019
Check your lot numberHow we source this data

Summary

Lupin Pharmaceuticals recalled Kaitlib Fe norethindrone and ethinyl starting Jul 2, 2019. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1565-2019 on Aug 7, 2019. Reason: Failed Impurities/Degradation Specifications: Kaitlib Fe Tablets has an out of specification result observed in long term stability study. Status: Terminated.

Why it was recalled

Failed Impurities/Degradation Specifications: Kaitlib Fe Tablets has an out of specification result observed in long term stability study.

Product description

Kaitlib Fe norethindrone and ethinyl estradiol chewable tablets (0.8 mg/0.025 mg) and Ferrous Fumarate, Chewable Tablets, Rx Only, Distributed by: Lupin Pharmaceuticals, Inc. Baltimore, MD - 21202 Manufactured by: Lupin Limited Pathampur -454775 India. NDC 68180-903-11 (wallet of 28 tablets) NDC 68180-903-13 (carton of 3 wallets)

Lot numbers, UPCs & expiration codes

Lot L800050

Where it was sold

Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1565-2019
Classification
Class II
Status
Terminated
Recall initiated
Jul 2, 2019
FDA report date
Aug 7, 2019
Quantity
12938 units
Recall type
Voluntary: Firm initiated
Recalling firm
Lupin Pharmaceuticals Inc.

Original FDA data

Every field from FDA enforcement report D-1565-2019, exactly as published.

Show all FDA fields
City
Baltimore
State
MD
Status
Terminated
Country
United States
Event ID
83284
Address
111 S Calvert St Fl 21ST
Code information
Lot L800050
Postal code
21202-6174
Report date
Aug 7, 2019
Product type
Drugs
Recall number
D-1565-2019
Classification
Class II
Recalling firm
Lupin Pharmaceuticals Inc.
Product quantity
12938 units
Termination date
Feb 16, 2021
Reason for recall
Failed Impurities/Degradation Specifications: Kaitlib Fe Tablets has an out of specification result observed in long term stability study.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Kaitlib Fe norethindrone and ethinyl estradiol chewable tablets (0.8 mg/0.025 mg) and Ferrous Fumarate, Chewable Tablets, Rx Only, Distributed by: Lupin Pharmaceuticals, Inc. Baltimore, MD - 21202 Manufactured by: Lupin Limited Pathampur -454775 India. NDC 68180-903-11 (wallet of 28 tablets) NDC 68180-903-13 (carton of 3 wallets)
Distribution pattern
Nationwide in the USA
Recall initiation date
Jul 2, 2019
Initial firm notification
Letter
Center classification date
Jul 30, 2019

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1565-2019, published Aug 7, 2019. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls